Skip to main content
. 2022 Apr 5;22:129. doi: 10.1186/s12883-022-02649-7

Table 2.

Neurologic characteristics of 53 patients with DPPX antibodies

No. (%)
Previous reported (n = 44) Ours (n = 9) Sum (n = 53)
Characteristics
 Cognitive disorders 32 (72.7) 7 (77.8) 39 (73.6)
 Brainstem or spinal cord disordersa 36 (81.8) 4 (44.4) 40 (75.5)
 Cerebellar ataxia 16 (36.4) 2 (22.2) 18 (34.0)
 Myoclonus or tremor 23 (52.3) 3 (33.3) 26 (49.1)
 Limb paralysis 0 (0) 2 (22.2) 2 (3.8)
 Psychosisb 14 (31.8) 1 (11.1) 15 (28.3)
 Headache 1 (2.3) 5 (55.6) 6 (11.3)
 Weight loss 25 (56.8) 3 (33.3) 28 (52.8)
 Sleep disordersc 17 (38.6) 4 (44.4) 21 (39.6)
 Mood disordersd 19 (43.2) 3 (33.3) 22 (41.5)
 Gastrointestinal symtomse 27 (61.4) 4 (44.4) 31 (58.5)
 Seizures 5 (11.4) 2 (22.2) 7 (12.2)
 Dysautonomiaf 17 (38.6) 3 (33.3) 20 (37.7)
 CSF elevated white cell account 16/33 (48.5) 2 (22.2) 18/42 (42.9)
 CSF elevated proteins 8/19 (42.1) 4 (44.4) 12/28 (42.9)
 Brain MRI abnormalities 9 (20.5) 8 (88.9) 17 (32.1)
 Brain MRI specific changes 1 (2.3) 7 (77.8) 8 (14.1)
 Tumor Screening 5 (11.4) 2 (22.2) 7 (13.2)

Abbreviations: DPPX dipeptidyl-peptidase-like protein-6, MRI Magnetic Resonance Imaging

a Abnormal eye movement; dysphagia; stiffness; dysarthria; respiratory failure; vertigo; hyperekplexia

b Delirium; hallucination; delusion

c Insomnia; hypersomnia; RBD

d Depression; anxiety; apathy; appetite loss

e Diarrhea; gastroparesis; constipation; abdominal pain

f Diaphoresis; temperature dysregulation; urinary symptoms